Chris Hillis: Reflections on My Term as President of the Canadian Hematology Society
Chris Hillis, Associate Professor at McMaster University, Former President of the Canadian Hematology Society, shared on LinkedIn:
”Sharing my reflection as I finish my term as President of the Canadian Hematology Society.
Hematology is, in many ways, a microcosm of medicine at its best.
It spans the full spectrum, from rare benign disorders to complex malignancies, from transfusion medicine to cutting-edge cellular therapies.
It is a discipline grounded equally in science and humanity, where laboratory insights translate directly to patient lives, often in profound and immediate ways.
Over the past years, it has been a privilege to witness the continued evolution of our field including new therapies, deeper biological understanding, and a growing national community committed to excellence, collaboration, and equity.
What has stood out most, however, is not just the pace of innovation, but the strength of our people.
Across Canada, hematologists are leading: in research, in clinical care, in education, and in advocacy. We are increasingly interconnected, increasingly collaborative, and increasingly intentional about the kind of community we are building.
It is in that spirit that I am especially pleased to pass the torch to Alina Gerrie (The University of British Columbia BC Cancer).
Alina brings a remarkable combination of clinical expertise, academic rigor, and thoughtful leadership.
She represents the best of Canadian hematology.
Alina is deeply grounded in patient care, actively engaged in advancing knowledge, and committed to mentorship and community-building. Her perspective from British Columbia adds further strength to our national voice, and I have no doubt that under her leadership, the Society will continue to grow.
The future of hematology in Canada is extraordinarily bright!
We are entering an era of precision medicine, of increasingly sophisticated therapeutics, and of expanding opportunities to improve outcomes across all domains of our specialty.
At the same time, we are being called to lead in new ways.
As hematologist we must address access, support trainees and early-career colleagues, and ensure that our systems evolve alongside our science.
I leave this role with confidence that CHS is well-positioned to meet these challenges and opportunities.
That confidence rests not only in Alina’s leadership, but in all of you who continue to define what it means to be a hematologist in Canada.
Thank you for the privilege of serving this community.
I look forward to supporting CHS in new ways and to watching its continued evolution in the years ahead.”
Stay updated with Hemostasis Today.
-
Jul 14, 2026, 15:03Heghine Khachatryan: Phase III Trial Results Support BAFF-R Inhibition in Corticosteroid-Refractory ITP
-
Jul 14, 2026, 14:51Nathan Connell: ISTH 2026 Highlights the Power of Lifelong Collaboration
-
Jul 14, 2026, 14:42Wolfgang Miesbach: VOYAGER1 Highlights Progress Toward Injection-Free Care in Hemophilia A
-
Jul 14, 2026, 12:08Elvira Grandone: Finding the Right LMWH Dose for Pregnant Patients Suffering From DVT
-
Jul 14, 2026, 12:05Eloïse Laouenan: From Washington to Paris – Join GETBO at ISTH 2026
-
Jul 14, 2026, 12:02Louise St. Germain Bannon: Our first ISTH regulatory session at ISTH 2026
-
Jul 14, 2026, 11:21Malwina Maliszewska: Advancing Coagulation Diagnostics at ISTH 2026
-
Jul 14, 2026, 11:07Mary Cushman: Honoring Outstanding Mentorship at ISTH 2026
-
Jul 14, 2026, 10:53Maha Othman: Advancing the Management of Inherited Thrombocytopenias at ISTH 2026